Jeff Waugh

Jeff Waugh

Auto-generated profile, based on publicly available information

Jeff Waugh

Division of Pediatric Neurology, University of Texas Southwestern, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SKSébastien Küry
Sébastien Küry
GWGeeske M. van Woerden
Geeske M. van Woerden
TBThomas Besnard
Thomas Besnard
MOMartina Proietti Onori
Martina Proietti Onori
XLXénia Latypova
Xénia Latypova
SMSandra Mercier
Sandra Mercier

28 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
XZXue Zeng
Xue Zeng
MSMichael C. Sierant
Michael C. Sierant
MKMichael C. Kruer
Michael C. Kruer

2 November 2017 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
MRMargot R F Reijnders
Margot R F Reijnders
RJRobert Janowski
Robert Janowski
MAMohsan Alvi
Mohsan Alvi
JSJay Self
Jay Self
TETon J van Essen
Ton J van Essen
DBDiana Baralle
Diana Baralle
Background: De novo mutations in PURA have recently been described to cause PURA syndrome, a neurodevelopmental disorder characterised by severe intellectual disability (ID), epilepsy, feeding difficulties and neonatal hypotonia. Objectives: To delineate the clinical spectrum of PURA syndrome and study genotype-phenotype correlations. Methods: Diagnostic or research-based exome or Sanger sequencing was performed in individuals with ID. We systematically collected clinical and mutation data on newly ascertained PURA syndrome individuals, evaluated data of previously reported individuals and performed a computational analysis of photographs. We classified mutations based on predicted effect using 3D in silico models of crystal structures of Drosophila-derived Pur-alpha homologues. Finally, we explored genotype-phenotype correlations by analysis of both recurrent mutations as well as mutation classes. Results: We report mutations in PURA (purine-rich element binding protein A) in 32 individuals, the largest cohort described so far. Evaluation of clinical data, including 22 previously published cases, revealed that all have moderate to severe ID and neonatal-onset symptoms, including hypotonia (96%), respiratory problems (57%), feeding difficulties (77%), exaggerated startle response (44%), hypersomnolence (66%) and hypothermia (35%). Epilepsy (54%) and gastrointestinal (69%), ophthalmological (51%) and endocrine problems (42%) were observed frequently. Computational analysis of facial photographs showed subtle facial dysmorphism. No strong genotype-phenotype correlation was identified by subgrouping mutations into functional classes. Conclusion: We delineate the clinical spectrum of PURA syndrome with the identification of 32 additional individuals. The identification of one individual through targeted Sanger sequencing points towards the clinical recognisability of the syndrome. Genotype-phenotype analysis showed no significant correlation between mutation classes and disease severity.

25 January 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MKMcKenna Kelly
McKenna Kelly
MPMeredith Park
Meredith Park
IMIvana Mihalek
Ivana Mihalek
ARAnne Rochtus
Anne Rochtus
MGMarie Gramm
Marie Gramm
APAnnapurna Poduri
Annapurna Poduri

1 August 2014 in Pediatric Neurology
Verified
Journal Article
Closed access
CGClaudio M. de Gusmão
Claudio M. de Gusmão
RGRejean M Guerriero
Rejean M Guerriero
MBMiya Elizabeth Bernson-Leung
Miya Elizabeth Bernson-Leung
DPDanielle Pier
Danielle Pier
PIPatricia I. Ibeziako
Patricia I. Ibeziako
JWJeff L. Waugh
Jeff L. Waugh

6 April 2016 in Journal of Child Neurology
Verified
Journal Article
Closed access
MDMarisela E. Dy
Marisela E. Dy
FCFlorence C. F. Chang
Florence C. F. Chang
SJSol De Jesus
Sol De Jesus
IAIrina Anselm
Irina Anselm
NMNeil Mahant
Neil Mahant
JWJeff L. Waugh
Jeff L. Waugh
ADCY5 mutations have been reported as a cause of early onset hyperkinetic movements associated with delayed motor milestones, hypotonia, and exacerbation during sleep. The movement disorder may be continuous or episodic, and can vary considerably in severity within families and in individuals. The authors report a case series of 3 patients with ADCY5 mutations treated with deep brain stimulation after unsuccessful medication trials. All had extensive imaging, metabolic, and genetic testing prior to confirmation of their ADCY5 mutation. Two of the patients had the c.1252C>T; p.R418W mutation, while the youngest and most severely affected had a de novo c.2080_2088del; p.K694_M696 mutation. All had variable and incomplete, but positive responses to deep brain stimulation. The authors conclude that deep brain stimulation may provide benefit in ADCY5-related movement disorders. Long-term efficacy remains to be confirmed by longitudinal observation. ADCY5 should be considered in the differential diagnosis of early onset hyperkinetic movement disorders, and may respond to deep brain stimulation.